Nuwellis Inc - SIC # 3845 - ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS

Ticker Exchange SIC # Website Latest Ticker
NUWE Nasdaq 3845 https://www.nuwellis.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Nuwellis Inc

Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health - Apr 9th, 2024 1:00 pm
Nuwellis Full Year 2023 Earnings: EPS Beats Expectations - Mar 8th, 2024 11:10 am
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference - Mar 7th, 2024 2:08 pm
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results - Mar 5th, 2024 1:00 pm
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 - Feb 27th, 2024 2:00 pm
Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™ - Feb 22nd, 2024 12:58 pm
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 20th, 2024 10:06 pm
Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference - Feb 20th, 2024 1:42 pm
New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload - Feb 6th, 2024 2:00 pm
Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter - Jan 4th, 2024 8:05 pm
New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients - Nov 28th, 2023 1:00 pm
Nuwellis, Inc. Announces Third Quarter 2023 Financial Results - Nov 7th, 2023 1:00 pm
Nuwellis Announces Board of Directors Transition - Nov 1st, 2023 12:00 pm
Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device - Oct 31st, 2023 12:00 pm
Nuwellis, Inc. To Announce Third Quarter 2023 Financial Results on November 7, 2023 - Oct 18th, 2023 8:15 pm
Nuwellis Announces Closing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants - Oct 17th, 2023 8:15 pm
Nuwellis Announces Pricing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants - Oct 13th, 2023 12:30 pm
Nuwellis Provides Regulatory Update on SeaStar Medical’s Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption - Oct 10th, 2023 12:00 pm
Nuwellis to Present at the Gilmartin Group Emerging Growth Showcase - Sep 11th, 2023 8:15 pm
Nuwellis, Inc. Announces Second Quarter 2023 Financial Results - Aug 8th, 2023 12:15 pm